PubRank

Padmanee Sharma

Author PubWeight™ 40.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015 12.74
2 CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008 3.04
3 Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010 2.73
4 B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007 2.37
5 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
6 PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014 2.06
7 Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 2009 1.74
8 The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011 1.56
9 Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov 2011 1.52
10 Harnessing the power of the immune system to target cancer. Annu Rev Med 2012 1.33
11 Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013 1.29
12 Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 2007 1.19
13 Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 2014 1.18
14 NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res 2009 1.14
15 Advances in the development of cancer immunotherapies. Trends Immunol 2012 0.96
16 Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 2008 0.93
17 Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 2011 0.90
18 Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol 2010 0.86
19 Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines 2010 0.84
20 CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy. Cancer Immunol Res 2013 0.82
21 Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity. Nat Rev Urol 2012 0.81
22 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
23 Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 2013 0.77
24 Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell 2015 0.76
25 Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017 0.75